Following Jinxin Reproduction's landing on the Hong Kong Stock Exchange in 2019, another assisted reproductive medical group launched a sprint to the Hong Kong Stock Exchange.
On December 22, Aviave Hospital Management Group was abbreviated as ***"Aviave"Submitted a prospectus on the Hong Kong Stock Exchange to be listed in a Hong Kong IPO.
Founded in 2006 in Shenzhen, Guangdong Province, AV is a one-stop assisted reproductive technology (ART) and assistive services provider, focusing on providing ART and auxiliary services for infertility patients through the company's four franchised hospitals, including Zhanjiang Jiuhe Hospital in Guangdong Province, Tianjin Aiwei Hospital in Tianjin, Jieyang Aiwei Hospital in Guangdong Province, and Kunming Aiwei Hospital in Yunnan Province, covering the whole process and post-service of diagnosis, fertility and assistance.
As of June 30, 2023, Aviave has more than 90,000 patients, undergoing 5More than 70,000 IVF cycles, completed 6More than 70,000 embryo transfers (including fresh embryo transfer and frozen embryo transfer), witnessed 3More than 30,000 IVF babies were born.
Relevant statistics show that in 2022, Aviaf ranked fourth among China's private assisted reproductive technology service providers, with a total of 6,706 IVF cycles, accounting for 09%。
In fact, according to incomplete statistics, since the beginning of this year, a number of medical groups have hit the market.
On December 19, 2023, the second-largest private oncology medical group in China, USA-China Jiahe, finally passed the hearing of the Hong Kong Stock Exchange and will be listed in the near future after three submissions by the Hong Kong Stock Exchange in May 2022, January 2023 and September 2023.
On February 28, **Fukang Medical Co., Ltd. submitted a prospectus to sprint to the main board of the Shanghai Stock Exchange. It is reported that the funds raised are intended to be used for the construction project of the central campus of ** Fukang Hospital, which fills the gap of ** regional non-tumor specialized hospitals.
On May 5, Sanbo Brain Department, the "first share of neurology", landed on the GEM of the Shenzhen Stock Exchange. As a representative of serious medical care and critical care care, Sanbo Brain Department focuses on the field of neurology, which is known for its high disciplinary barriers. At present, it operates 6 hospitals with a total of about 9,000 open beds.
On July 5, Lu Daopei Medical Group, the largest hematology medical service institution in China, submitted a prospectus in Hong Kong to be listed on the main board of Hong Kong. It is reported that this is also its second submission after the submission of the form expired on January 3 this year.
It can be seen that compared with previous years, consumer medical care such as dentistry and ophthalmology actively impacted the listing, this year's "listing activists" are concentrated in serious medical fields such as hematology, tumors, and assisted reproduction.
The advantage of serious medical services is that the technical threshold and investment threshold are relatively high, which can form professional barriers and belong to "scarce specialties". Even if capital understands that the track is developing well, it will also consider talent and technology issues, so it will not rush in, so that the market will be quickly saturated, and then intensify the homogeneous competition in the industry.
It is foreseeable that the development of private medical care to high-quality specialties has become a trend, and it is expected that more high-quality private specialized hospitals will emerge in the future.
Article**: Huaxia Medical Network (sharing medical management strategies, serving hospital trading).